INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that are widely distributed in the human brain where they have a modulatory function associated with numerous transmitter systems. The major nAChR subtypes present in the mammalian brain are a7 and a4b2 (Lindstrom et al, 1995; Holladay et al, 1997) . The majority of brain nAChRs with a high affinity for agonists contain a4 and b2 subunits (Picciotto et al, 1995; Marubio et al, 1999) . (Flores et al, 1992; Sihver et al, 1998; Zoli et al, 1998) .
Reductions in nAChR density have been identified in a number of neurodegenerative disorders including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD) (Rinne et al, 1991; Perry et al, 1995; Court et al, 2000a) . In AD, binding assays with (Warpman and Nordberg, 1995) and immunochemical analysis (Martin-Ruiz et al, 1999; Wevers et al, 1999; Guan et al, 2000; Burghaus et al, 2000) indicate that the major contributor to loss of nAChRs in cortical areas is the a4 subunit. Deficits in [ 11 C]nicotine binding in the hippocampus, temporal and frontal cortex have also been reported in vivo in AD (Paterson and Nordberg, 2000) . In PD, the majority of reports indicate deficits in high-affinity nicotinic agonist binding in both the caudate and putamen (Perry et al, 1990a; Rinne et al, 1991; Aubert et al, 1992a; Court et al, 2000b) , in parallel with the decline in dopaminergic markers (Piggott et al, 1999) . Reduced [ 3 H ]nicotine binding in the substantia nigra (SN) pars compacta and ventral tegmental area has also been reported in PD (Perry et al, 1995) . In DLB, losses in [ 3 H]nicotine binding have been reported in the striatum, the SN pars compacta and pars reticulata, and the dorsolateral tegmentum (Perry et al, 1995; Court et al, 2000b) .
5-Iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380) is a high-affinity nAChR ligand that demonstrates high subtype selectivity for a4b2 nAChRs (Mukhin et al, 2000) . A recent study has also shown 5-I-A-85380 binding to aconotoxin MII-sensitive (a6b2) nAChRs in the rodent and monkey striatum (Kulak et al, 2002) . The development of an in vivo a4b2 subtype-selective nAChR imaging agent will allow studies following disease progression, identifying where and when during the disease process nAChR deficits occur, and also provide information on how nAChR's expression relates to symptomatology and therapeutic response.
The present study investigates the distribution of 5-[ 
MATERIALS AND METHODS

Materials
The trimethylstannyl precursor (TMS precursor) of 5-[ ]-A-85380 was synthesized via a modification of a previously published method by Zoghbi et al (2001) . Aliquots (300 mg) of TMS precursor were stored in nitrogen-filled, silanized vials at À181C. A measure of 74 MBq, carrier free, Na 125 I in B18 ml of 0.01-0.1 M NaOH was obtained and was made up to 200 ml using 0.01 M NaOH. The radioiodination reaction was prepared by adding 20 ml 2 M HCl to the activity followed by addition of a mixed solution of 300 mg of precursor in 100 ml ethanol.
The reaction was initiated by adding 50 ml (50 mg) of Chloramine T and the reaction mixture was then mixed by vortex. Mixing was continued during an incubation period of 15 min at 651C. The reaction was quenched by addition of 100 ml (100 mg) NaHSO 4 . Deprotection was achieved by addition of 200 ml of trifluoroacetic acid and mixing. Mixing was continued during an incubation period of 15 min at 651C.
Purification of 5-[ 125 I]-A-85380 was carried out by injection of the reaction mixture onto a reverse phase C-18 semi-preparative column (Synergi Hydro 4 mm 10 Â 150 mm) at a flow rate of 3 ml/min. The fraction containing 5-[
125 I]-A-85380 was collected and the solvent removed by rotatory evaporation. Reconstitution of the purified 5-[
125 I]-A-85380 was carried out with sterile 0.9% saline solution through a 0.22 mm filter. The 5-[ 125 I]-A-85380 obtained was then stored at À201C. Analytical HPLC of an aliquot of the final product was carried out on a reverse phase C-18 analytical column (Synergi Hydro 4 mm, 4.6 Â 150 mm) at a flow rate of 1 ml/min.
Stability of 5-[ 125 I]-A-85380
The stability of 5-[ 125 I]-A-85380 in saline was investigated over time at À201C. Samples were stored and analyzed at 5 1 2 , 9, and 13 weeks. Samples were injected on to a reverse phase C-18 analytical column (Synergi Hydro 4 mm, 4.6 Â 150 mm) at a flow rate of 1 ml/min.
Brain Tissue
Joint Ethics Committee of Newcastle and North Tyneside Health Authority rules and MRC brain banking procedures were followed and consent of next of kin was obtained in the collection of all brain tissue. Coronal slices from the left hemisphere were obtained postautopsy and were rapidly frozen in liquid arcton cooled over liquid nitrogen. The slices were stored at À701C.
For the distribution study, tissue from 16 control cases was used. Demographic details of control cases are shown in Table 1 . Smoking histories were obtained, one smoker was excluded from the study and ex-smokers identified. The control group studied had not been exposed to neuroleptic medication. Tissue blocks were obtained containing striatum, globus pallidus, insula and cingulate cortices as well as blocks of anterior thalamus, temporal cortex, occipital cortex, frontal cortex, and cerebellum. Not all areas studied were available in every case.
For the disease study, tissue from 16 controls cases, 24 DLB cases, 8 AD cases, 4 mild AD cases, 10 VaD cases, and 10 PD cases was used. Demographic details of cases are shown in Table 1 . No significant differences in age were seen between groups. Smoking histories were obtained for all groups, one smoker was excluded from the study and exsmokers identified. Neuroleptic drug histories were also identified. None of the cases used in this study were exposed to cholinesterase inhibitors. Tissue blocks were obtained containing striatum, globus pallidus, insula and cingulate cortices as well as blocks of anterior thalamus and temporal cortex. The majority of areas were obtained from most cases.
For autoradiography, sections were cut by cryostat (20 mm) and dried on to Vecta-bond-coated slides at room temperature before storage in sealed boxes at À701C.
Neuropathological Diagnosis
At post-mortem, the right hemisphere was formalin fixed for at least 3 months. AD pathology was evaluated using quantitative techniques to determine plaque and tangle densities (Perry et al, 1990b) . Sections of cortical areas were stained with a modification of Palmgren's silver technique for neurofibrillary tangle quantification (Cross, 1982) . The von Braunmühl silver impregnation technique was used to demonstrate plaques. For each neocortical area, the mean tangle density was obtained in consecutive fields (0.61 mm 2 / area) through the full width of the cortical ribbon in five randomly marked positions around gyri; the mean plaque density was calculated from counts in fields (3.1 mm 2 /area) at five similarly marked points. Tangle and plaque densities in the whole of the neocortex were expressed as mean values per mm 2 . Braak staging was determined (Braak and Braak, 1991) and AD was defined as Braak stage V and VI. Mild AD was defined as cases with no clinical confirmation of dementia but demonstrating senile plaque densities diagnostic for possible AD and neurofibrillary changes characteristic of early AD (Braak stage pIII). a-Synuclein immunohistochemistry (Novocastra Laboratories Ltd, Newcastle, UK) was used to demonstrate Lewy bodies (LB) and Lewy neurites. Cortical LB frequency was assessed according to the consensus guidelines for diagnostic rating protocol of DLB (McKeith et al, 1996) , which have been modified for a-synuclein, an LB pathology marker more sensitive than the earlier recommended ubiquitin. Scoring for each cortical area for a-synuclein was: 0 ¼ no LB, 1 ¼ up to five LB, 2 ¼ 5-20 LB plus few neurites, 3 ¼ 20-40 LB plus moderate neurites, 4 ¼ over 40 LB plus dense neurites. Controls had no evidence of neurological disease. Controls were assessed neuropathologically, and did not show AD pathology or LB commensurate with a diagnosis of AD or other neurodegenerative disease. No significant vascular pathology was seen in controls.
Autoradiography Procedures
Prior to assay, sections were left to air dry at room temperature. Adjacent sections were prewashed in Tris-HCl pH 7.4 buffer, containing 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , and 1 mM MgCl 2 , for 20 min at room temperature to remove endogenous ligand. For total binding, sections were incubated in the same buffer as prewash and 22 pM 5-[ has been reported to be 12 pM in the human brain (Mukhin et al, 2000) ; therefore, at the above concentration binding approaches B max . A measure of 1 mM epibatidine was added to at least one adjacent section from each case to give a measure of nonspecific binding. After incubation, sections were washed for 2 Â 10 min in the same buffer at 41C and dipped into distilled water at 41C. Sections were then left to air dry for 1 h before exposure to Kodak Biomax MR film (24 Â 30 cm) with 125 I autoradiographic microscale standards at 41C. After 48 h exposure, the films were warmed to room temperature (2 h) before development using 500 ml D19 for 5 min, stopped using 500 ml 1% aqueous acetic acid for 1 min, fixed using 500 ml 25% Unifix for 6 min, and washed for 20 min in running water. Films were left to air dry for 2 h. Binding was quantified to 125 I standards using MCID M5+ image analysis system (Imaging Research Ltd, Interfocus, UK) to give binding in fmol/mg of tissue. Specific binding was calculated by subtraction of non-specific binding from mean total binding.
Statistical Analysis
Binding data in control and disease groups were analyzed by one-way ANOVA with post hoc analysis using Fisher's multiple comparison of means. Differences, between groups, in age and post-mortem delay were analyzed by one-way ANOVA with post hoc analysis using Fisher's multiple comparison of means, and correlations between binding and demographic factors were analyzed by Pearson's product moment correlation. Binding data in ex-smokers and non-smokers, and neuroleptic exposed and non-exposed, were analyzed by one-way ANOVA with post hoc analysis using Fisher's multiple comparison of means. Analysis was carried out using Minitab (Release 13, Minitab Inc.)
RESULTS
Radiochemistry
Modification of a previously reported method (Zoghbi et al, 2001) has allowed radiolabelling and purification of 5- 125 IA via a more rapid, one-pot synthesis method. 5-[
125 I]-A-85380 was successfully obtained with a radiochemical purity of 498% and an isolated radiochemical yield of 60.2%. The specific activity of the product was calculated to be 2580 Ci/mmol.
Stability of 5-[ 125 I]-A-85380 in Saline
After 9 weeks, the radiochemical purity of 5-[ 125 I]-A-85380 stored at À201C was found to be 96.9% 7 3.0 (n ¼ 2). By 13 weeks, the radiochemical purity of 5-[ 125 I]-A-85380 stored at À201C was reduced to 61.1% 7 2.6 (n ¼ 4). All auto- 
There are no significant differences between the groups except for a significantly longer post-mortem (PM) delay in the mild AD group (one-way ANOVA). PM delay in the mild AD group does not correlate with 5-[
125 I]-A-85380 binding in any areas measured. The known smoker has been eliminated and ex-smokers have been identified in these data. n ¼ number of cases.
radiography assays were completed within 6 weeks after the synthesis of 5-[
125 I]-A-85380.
Effects of Demographic Variables, Neuroleptic and Smoking Histories
There were no significant correlations in 5-[ 125 I]-A-85380 binding with age and post-mortem delay. In addition, no significant differences in 5-[
125 I]-A-85380 binding were found between ex-smokers and non-smokers in all areas studied in the control group in the distribution study and in all groups in the disease study. Binding in the striatum and insular cortex in ex-and non-smokers is shown in Table 2 . Exposure to neuroleptic medication was also shown not to affect 5-[
125 I]-A-85380 binding, with no significant differences seen between exposed and non-exposed cases within disease groups (Table 3) (Figure 1f) . Moderate binding was also found in the visual area (Brodmann Area (Ba) 17) and secondary visual area (Ba18), in particular middle and lower layers (0.50 7 0.08 and 0.48 7 0.126 fmol/mg), in the occipital lobe (Figure 1e ) and moderate binding was also found in the auditory association area (Ba21), Ba20, and Ba36 in the temporal cortex (0.44 7 0.11, 0.45 7 0.17, and 0.46 7 0.08 fmol/mg, respectively) (Figure 1f ). The striatal binding was moderate with slightly higher binding in the caudate (0.57 7 0.17 fmol/mg) than putamen (0.56 7 0.19 fmol/mg), whereas binding in the globus pallidus (GP) was largely absent (Figure 1b) . Also highlighted with moderate binding were white matter tracts in the occipital (Figure 1e ), frontal (Figure 1c) , and temporal lobes (Figure 1f) where binding was generally 3-to 5-fold greater than white matter (0.26 7 0.06 and 0.48 7 0.13 fmol/ mg). No measurable non-specific binding of 5-[ 125 I]-A-85380 was apparent in any areas studied when binding was displaced by 1 mM epibatidine. An example of non-specific binding in a section of striatum, anterior thalamus, and adjacent tissue is illustrated in Figure 1d .
Disease comparisons. Striatal 5-[
125 I]-A-85380 binding in AD, DLB, and PD tended to be lower than both control and VaD cases (Table 4) , reaching significance in the caudate (F(6,58) ¼ 6.8, po0.05, o0.001, and o0.001, respectively) and in the putamen in only the DLB and PD groups (F(6,60) ¼ 6.94, po0.001 and o0.001, respectively). In addition, 5- There are no significant differences related to exposure (one-way ANOVA). n ¼ number of cases. There are no significant differences between the groups (one-way ANOVA). n ¼ number of cases.
[ 3 H]nicotine binding in human brain in non-and exsmokers (Court et al, 1998) . In addition, there were no significant differences in 5-[
125 I]-A-85380 binding between patients exposed and not exposed to neuroleptic medication in all groups and areas studied. Previous post-mortem studies have shown neuroleptic medication to be associated with accentuation of [ 3 H]nicotine binding deficits in the caudate nucleus (Court et al, 2000b) . Results from this study suggest that neuroleptic medication may affect nAChRs other than the a4b2 subtype.
Distribution in Normal Tissue
In vitro visualization of 5-[ 125 I]-A-85380 receptor distribution has previously been carried out in rats (Mukhin et al, 2000) and mice (Musachio et al, 1998; Horti et al, 1999) . In the present study, the binding distribution of 5-[
125 I]-A-85380 in human post-mortem tissue was found to be consistent with [ 
a6 and b2 subunits (Grady et al, 2001; Champtiaux et al, 2002) and therefore striatal binding evident in the present study is likely to reflect both a4b2 and a6b2 subtype distributions. [ 125 I]-a-conotoxin MII binding in mouse brain has also been shown to be high in the superficial layers of the superior colliculus, nigrostriatal pathways, optic tract, olivary pretectal, mediolateral and dorsolateral geniculate nuclei (Whiteaker et al, 2000) and therefore 5- (Court et al, 2000a) .
In the cerebellum, 5-[ (Court and Perry, 1995a) . Moderate 5-[
125 I]-A-85380 binding was also present in the dentate nucleus. Immunohistochemical localization of nicotinic receptors in the cerebellum has shown a number of receptor subunits, including both a4 and a6, to be present in molecular and granule cell layer and therefore 5-[
125 I]-A-85380 binding in the cerebellum may not be solely due to a4 but also to a6 subunit containing receptors. Cerebellar dysfunction has been implicated in attentional deficits. Nicotinic receptor agonists enhance attentional function and in autism a4 subunit abnormalities have been highlighted in the cerebellum (Lee et al, 2002) and therefore 5-I-A-85380 imaging may be useful in identifying abnormalities in this area in vivo.
In the occipital cortex, 5-[
125 I]-A-85380 binding appears to be concentrated in the visual cortex (Ba17) and the secondary visual area (Ba18), with highest levels in lower cortical layers, consistent with the specific action of acetylcholine in vision (Nobili and Sannita, 1997) . Acetylcholine is thought to serve both sensory and cognitive processes involved in vision, and 5-[
125 I]-A-85380 binding in the LG nucleus may reflect the 'gating' of sensory information to the visual cortex.
Binding of 5-[ 125 I]-A-85380 in white matter in the temporal, occipital, and cingulate cortices appears to course with cholinergic pathway previously observed using acetylcholinesterase histochemistry (Selden et al, 1998) . Binding of 5-[
125 I]-A-85380 shown in the temporal cortex follows the course of the capsular division of the lateral cholinergic pathway. Fibers of this pathway run adjacent to the putamen in the medial aspect of the external capsule into the nucleus basalis of Meynert which then project down into the temporal cortex (Selden et al, 1998) . Binding of 5-[ 125 I]-A-85380 to fibers in the external capsule was not clearly seen due to moderate binding seen in the putamen and claustrum; however, binding to fibers running from the nucleus basalis of Meynert into the temporal cortex was clearly highlighted. The binding of 5-[
125 I]-A-85380 in the occipital lobe white matter correlates with lateral and medial cholinergic pathways merging posteriorly in the occipital lobe (Selden et al, 1998) . 5-[
125 I]-A-85380 binding at the tip of the cingulate gyrus correlates with the medial cholinergic pathway supplying the cingulate gyrus (Selden et al, 1998) . Streaks of intense [ 3 H]nicotine white matter binding previously seen in foetal cerebellum and temporal lobe may also reflect the presence of nAChRs along The known smoker has been eliminated from these data and ex-smokers are included. cholinergic axons (Court et al, 1995b , probably visible in fetal tissue because quenching of [ 3 H]nicotine is reduced due to lower myelination. It is reasonable to conclude that neuronal a4b2 (or possibly a6b2) receptors are located along cholinergic nerve fiber tracts possibly indicative of preassembled receptors being transported from the cell body along axons to terminals. A cholinergic fiber loss in cortical areas has previously been reported in AD brains compared to controls (Geula and Mesulam, 1996) and therefore 5-I-A-85380 may be useful in highlighting these deficits in vivo in humans. Further investigation into cortical areas in disease post-mortem tissue may show 5-I-A-85380 to be useful diagnostically, highlighting deficits in cholinergic pathways.
Disease Comparisons
Alzheimer's disease. Reports on the density of nAChRs in the striatum in AD are inconsistent with studies reporting both loss and preservation of agonist binding in the caudate and putamen (Shimohama et al, 1986; Perry et al, 1989; Rinne et al, 1991; Aubert et al, 1992a) . In this study, posterior striatal levels were investigated and deficits in 5-[
125 I]-A-85380 binding in the caudate differentiated the AD group from controls. Deficits in striatal nAChRs do not appear, at least in some patients, to be associated with nigrostriatal dopaminergic deficits (Piggott et al, 1999) and are therefore more likely to be related to reduced striatal afferents from other sources, such as cortical areas subject to atrophy in AD and possibly thalamic areas. It may be that these striatal nAChRs deficits are responsible for disorders of movement observed in late stages of AD (Court et al, 2000a) . ]-A-85380 in thalamic nuclei was seen in AD; however, this did not reach statistical significance confirming earlier reports of no major deficits in thalamic areas in AD (Xuereb et al, 1990; Court et al, 2001 (Court et al, 2000b) . In DLB, deficits in striatal M1 muscarinic acetylcholine receptors (mAChRs), measured using [ 125 I]-A-85380 binding seen in both the striatum and substantia nigra in DLB, comparable to that in PD, could potentially be a marker of early degeneration, possibly highlighting deficits in nigrostriatal inputs, as SN dopaminergic neuron loss is greater in PD than in DLB (Piggott et al, 1999) , or deficits in other cortical inputs.
A (Court et al, 2000b) and also the loss of nigrostriatal dopaminergic markers (Piggott et al, 1999) . A study with 5-[ ]epibatidine in control human and PD brains showed a similar decrease of 40-50% in binding of both radioligands in the striatum .
In the SN, reduced 5-[ 125 I]-A-85380 binding also differentiated PD from controls and AD cases, highlighting the loss of dopaminergic nuclei projecting to the striatum. This finding is in agreement with evidence of reduced [ 3 H] nicotine binding in the SN pars compacta and ventral tegmental area (Perry et al, 1995) .
Reduced 5-[ 125 I]-A-85380 binding in the entorhinal cortex also differentiates PD from controls, supporting a number of studies demonstrating a deficit in nAChRs with highaffinity agonists and ChAT activity in the neocortex in PD (Whitehouse et al, 1988; Rinne et al, 1991; Aubert et al, 1992b; Perry et al, 1993; Lange et al, 1993) .
Thalamic 5-[ 125 I]-A-85380 binding in the PD group tended to be lower than controls, with significance reached in the APr thalamic nucleus, the reticular nucleus, and also STH nucleus. Thalamic 5-[
125 I]-A-85380 binding in PD also tended to be lower than in DLB, with significance reached in the STH nucleus. Dopamine deficiency in PD causes the disinhibition and overactivity of the STH nucleus and its projections to the internal GP, which in turn overinhibits thalamocortical projections which is thought to be responsible for the appearance of symptoms such as akinesia, rigidity, and perhaps tremor (Henderson and Dunnett, 1998) 125 I]-A-85380 binding in striatal areas in AD, DLB, and PD and in the substantia nigra in DLB and PD differentiates these groups from VaD as well as controls. This could be valuable in differentiating VaD from primary degenerative dementia. It must be noted, however, that these differences were not seen between mild AD and VaD.
In summary, 5-[ 125 I]-A-85380 binding reflects the previously reported distribution of a4b2 receptors in human brain and also differences of nAChRs seen with high-affinity agonists in age-related degenerative diseases. Significant differences were not only observed between dementia cases and controls but also between cases with different causes of dementia. Therefore, 5-[
125 I]-A-85380 is potentially a useful in vivo tool to aid specific diagnosis that is important in terms of treatment and management strategies.
